ERBB2 and lung cancer: Indeed, the fact that KRT19 is localized to the cell membranes in HER2-positive lung cancer cells supports the hypothesis that KRT19 binds to HER2 and activates it at the intracellular level, resulting in the further activation of downstream effectors.